Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

about

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

Item

http://www.wikidata.org/entity/Q46300809

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Single nucleotide polymorphism ...... enrolled in the FIRE-3 trial.

@en

Single nucleotide polymorphism ...... enrolled in the FIRE-3 trial.

@nl

type

Item

label

Single nucleotide polymorphism ...... enrolled in the FIRE-3 trial.

@en

Single nucleotide polymorphism ...... enrolled in the FIRE-3 trial.

@nl

prefLabel

Single nucleotide polymorphism ...... enrolled in the FIRE-3 trial.

@en

Single nucleotide polymorphism ...... enrolled in the FIRE-3 trial.

@nl

P1476

Single nucleotide polymorphism ...... s enrolled in the FIRE-3 trial

@en

P2093

Afsaneh Barzi

http://www.w3.org/2001/XMLSchema#string

Diana Hanna

http://www.w3.org/2001/XMLSchema#string

Jordan D West

http://www.w3.org/2001/XMLSchema#string

Martin D Berger

http://www.w3.org/2001/XMLSchema#string

Mitsukuni Suenaga

http://www.w3.org/2001/XMLSchema#string

Roel F Gopez

http://www.w3.org/2001/XMLSchema#string

Satoshi Okazaki

http://www.w3.org/2001/XMLSchema#string

Sebastian Stintzing

http://www.w3.org/2001/XMLSchema#string

Shu Cao

http://www.w3.org/2001/XMLSchema#string

Volker Heinemann

http://www.w3.org/2001/XMLSchema#string

P2860

The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

Therapeutic destruction of insulin receptor substrates for cancer treatment.

P304

383-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.30715

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

141

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28369940

http://www.w3.org/2001/XMLSchema#string

P921

single-nucleotide polymorphism

P932

5510747

http://www.w3.org/2001/XMLSchema#string